Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

LJLi JCJChunyan JiTZTaigang Zhu

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals prognostic factors impacting survival in acute myeloid leukemia with FLT3-TKD mutations, suggesting treatment implications.

Key Points

  • Overall survival in patients with FLT3-TKD mutations showed a median of 34.0 months, with a significant association to treatment response.
  • A comprehensive multivariate analysis was conducted to assess the prognostic factors affecting overall and event-free survival.
  • Use of intensive chemotherapy was prominent among patients, with 63.6% receiving this treatment regimen compared to those on alternative therapies.
  • The findings call for focus on the impact of FLT3 mutations and personalized therapy strategies in acute myeloid leukemia.

Cite This Study

J et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da11https://doi.org/10.1182/blood-2025-5182
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: Insights from real-world genomic data2025
  2. 2Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.2025 · 3 citations
  3. 3Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)2025 · 1 citations
  4. 4Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation2025 · 1 citations
  5. 5DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors2025 · 2 citations